Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
The immunotherapy, called cretostimogene, is delivered into the bladders of patients. It reduced the risk of tumor recurrence by 68%.
News Search
Search Results
The immunotherapy, called cretostimogene, is delivered into the bladders of patients. It reduced the risk of tumor recurrence by 68%.